New cancer drug combo tested in patients out of options
NCT ID NCT05427396
Summary
This early-stage study tested the safety of a new two-drug immunotherapy combination (JS004 plus toripalimab) in patients with advanced solid tumors that had stopped responding to standard treatments. The trial enrolled 31 adults with cancers like liver, esophageal, and cervical cancer to see if the drugs were safe and if they showed any early signs of helping control the disease. The main goal was to check for side effects, not to cure the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Conditions
Explore the condition pages connected to this study.